Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS
Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, […]
BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies
BenevolentAI, a leader in the development of cutting-edge AI that accelerates biopharma discovery, announces the […]
NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
NeuroSense Therapeutics, a company developing treatments for severe neurodegenerative diseases, today announced the completion of […]
Eikonoklastes Announces Formation of Scientific Advisory Board
Eikonoklastes Therapeutics, a biopharmaceutical company developing a novel gene therapy platform to discover and develop […]
Muscular Dystrophy Association Celebrates FDA Approval of Biogen’s Qalsody for Treatment of SOD1-ALS
The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) accelerated approval […]
Landmark Study Finds Pison AI Technology Can Detect Neurological Disorder in ALS Patients
Pison, the pioneers behind AI-powered neural biosensors for health, wellness, and 3D touchless smart device […]
ProJenX Announces Formation of Scientific Advisory Board for Development of ALS Treatment
ProJenX, a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment […]
NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS
NeuroSense Therapeutics, a company developing treatments for severe neurodegenerative diseases, today announced it has signed […]
Ionis Accounces FDA Advisory Committee Voted Unanimously for a Potential Accelerated Approval of Tofersen for SOD1-ALS
Ionis has announced the outcome of the United States Food and Drug Administration’s (FDA) Peripheral […]
Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics, a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more